Literature DB >> 23929839

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.

Aaron Flanders, Maryalice Stetler-Stevenson, Ola Landgren.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23929839      PMCID: PMC3739032          DOI: 10.1182/blood-2013-05-506170

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.

Authors:  Dingsheng Liu; Pei Lin; Ying Hu; Yi Zhou; Guilin Tang; Linda Powers; L Jeffrey Medeiros; Jeffrey L Jorgensen; Sa A Wang
Journal:  J Clin Pathol       Date:  2012-06-08       Impact factor: 3.411

2.  Treating myeloma: the future is already here!

Authors:  Ola Landgren; Neha Korde
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

3.  Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology.

Authors:  Elisa Cannizzo; Emanuele Bellio; Aliyah R Sohani; Robert P Hasserjian; Judith A Ferry; Michelle E Dorn; Craig Sadowski; Janessa J Bucci; Giovanni Carulli; Frederic Preffer
Journal:  Cytometry B Clin Cytom       Date:  2010-07       Impact factor: 3.058

4.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.

Authors:  Bruno Paiva; Joaquin Martinez-Lopez; Maria-Belen Vidriales; Maria-Victoria Mateos; Maria-Angeles Montalban; Elena Fernandez-Redondo; Lourdes Alonso; Albert Oriol; Ana-Isabel Teruel; Raquel de Paz; José-Garcia Laraña; Enrique Bengoechea; Alejandro Martin; Joaquin Diaz Mediavilla; Luis Palomera; Felipe de Arriba; Joan Bladé; Alberto Orfao; Juan-Jose Lahuerta; Jesus F San Miguel
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

5.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Authors:  Andy C Rawstron; Alberto Orfao; Meral Beksac; Ludmila Bezdickova; Rik A Brooimans; Horia Bumbea; Klara Dalva; Gwenny Fuhler; Jan Gratama; Dirk Hose; Lucie Kovarova; Michael Lioznov; Gema Mateo; Ricardo Morilla; Anne K Mylin; Paola Omedé; Catherine Pellat-Deceunynck; Martin Perez Andres; Maria Petrucci; Marina Ruggeri; Grzegorz Rymkiewicz; Alexander Schmitz; Martin Schreder; Carine Seynaeve; Martin Spacek; Ruth M de Tute; Els Van Valckenborgh; Nicky Weston-Bell; Roger G Owen; Jesús F San Miguel; Pieter Sonneveld; Hans E Johnsen
Journal:  Haematologica       Date:  2008-02-11       Impact factor: 9.941

  5 in total
  35 in total

1.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

2.  Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.

Authors:  Elisabet E Manasanch; Dalia A Salem; Constance M Yuan; Nishant Tageja; Manisha Bhutani; Mary Kwok; Dickran Kazandjian; George Carter; Seth M Steinberg; Diamond Zuchlinski; Marcia Mulquin; Katherine Calvo; Irina Maric; Mark Roschewski; Neha Korde; Raul Braylan; Ola Landgren; Maryalice Stetler-Stevenson
Journal:  Leuk Lymphoma       Date:  2014-10-30

Review 3.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

4.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Authors:  Neha Korde; Mark Roschewski; Adriana Zingone; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Nishant Tageja; Dickran Kazandjian; Sham Mailankody; Peter Wu; Candis Morrison; Rene Costello; Yong Zhang; Debra Burton; Marcia Mulquin; Diamond Zuchlinski; Liz Lamping; Ashley Carpenter; Yvonne Wall; George Carter; Schuyler C Cunningham; Verena Gounden; Tristan M Sissung; Cody Peer; Irina Maric; Katherine R Calvo; Raul Braylan; Constance Yuan; Maryalice Stetler-Stevenson; Diane C Arthur; Katherine A Kong; Li Weng; Malek Faham; Liza Lindenberg; Karen Kurdziel; Peter Choyke; Seth M Steinberg; William Figg; Ola Landgren
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

Review 5.  Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Authors:  Shalin Kothari; Jens Hillengass; Philip L McCarthy; Sarah A Holstein
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

6.  The current status of minimal residual disease assessment in myeloma.

Authors:  S K Kumar; S V Rajkumar
Journal:  Leukemia       Date:  2014-02       Impact factor: 11.528

Review 7.  Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Authors:  Sham Mailankody; Neha Korde; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; Maryalice Stetler-Stevenson; Ola Landgren
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

8.  Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias.

Authors:  Dominik F Draxler; Lisa M Wutzlhofer; Georg Slavka; Wolfgang Hübl; Heinz Ludwig; Martin Schreder; John Reynolds; Martin Willheim
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-07       Impact factor: 0.900

9.  Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Paul K Wallace
Journal:  Curr Protoc Cytom       Date:  2019-07-17

Review 10.  Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

Authors:  Christopher S Hourigan; Philip McCarthy; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-27       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.